What’s Ahead for Adaptimmune Therapeutics plc (ADAP) After Today’s Huge Increase?

March 14, 2018 - By Kenneth Lin

The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) is a huge mover today! The stock increased 5.38% or $0.47 during the last trading session, reaching $9.21. About 614,457 shares traded or 40.52% up from the average. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has declined 43.56% since March 14, 2017 and is downtrending. It has underperformed by 60.26% the S&P500.
The move comes after 6 months positive chart setup for the $862.85 million company. It was reported on Mar, 14 by Barchart.com. We have $10.04 PT which if reached, will make NASDAQ:ADAP worth $77.66 million more.

Analysts await Adaptimmune Therapeutics plc (NASDAQ:ADAP) to report earnings on March, 15 before the open. They expect $-0.25 EPS, down 13.64 % or $0.03 from last year’s $-0.22 per share.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Coverage

Among 5 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Adaptimmune Therapeutics PLC had 5 analyst reports since February 25, 2016 according to SRatingsIntel. The rating was initiated by Citigroup on Thursday, February 25 with “Buy”. The firm earned “Buy” rating on Tuesday, June 6 by Cowen & Co. SunTrust maintained the stock with “Buy” rating in Saturday, November 11 report. The firm earned “Underperform” rating on Monday, October 24 by Bank of America.

More news for Adaptimmune Therapeutics plc (NASDAQ:ADAP) were recently published by: Quotes.Wsj.com, which released: “Adaptimmune Therapeutics PLC ADR ADAP (US: Nasdaq)” on November 29, 2014. Marketwatch.com‘s article titled: “Adaptimmune Therapeutics PLC ADR” and published on March 04, 2016 is yet another important article.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $862.85 million. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The company's lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: